Meta-analysisPain Science & Central SensitizationSystematic Reviews & Meta-analysesComorbidities & Related ConditionsClinical RelevanceDOI
4 min read
Jump to:

Patient-friendly summary

If you read nothing else

Combining 17 trials, this review found that talk therapies (CBT and ACT) may modestly ease the depression and anxiety that often come with fibromyalgia, especially when used alongside standard medical care.

Bottom line

CBT and ACT appear to produce modest, statistically significant reductions in depression and smaller reductions in anxiety in fibromyalgia, supporting their use within integrated, multicomponent care rather than as standalone cures.

Moderate evidence

Published

2024
2 years ago
Current

Evidence hierarchy

Meta-analysis ◀ this study
Systematic Review
RCT
Cohort
Case-Control
Case Report
Expert Opinion

Study participants

1,499 participants across 17 randomized clinical trialsNot reportedPredominantly women (not reported as a precise split)

Adults with fibromyalgia confirmed by a rheumatologist (American College of Rheumatology criteria); samples were predominantly women and demographically homogenous

Full research — for clinicians and curious readers

Study Summary

This systematic review and meta-analysis pooled 17 randomized clinical trials (1,499 adults with rheumatologist-confirmed fibromyalgia) to examine whether cognitive-behavioral therapy (CBT) and acceptance and commitment therapy (ACT) reduce co-occurring depression and anxiety. Thirteen trials used CBT and four used ACT, with interventions averaging about 10 sessions of roughly 95 minutes each. Pooled analysis found a statistically significant but modest-to-moderate benefit for depression (standardized mean difference −0.31, 95% CI −0.47 to −0.15) and a smaller but still significant effect for anxiety (SMD −0.15, 95% CI −0.29 to −0.02). The authors conclude both approaches may be reliably incorporated into integrated, multicomponent fibromyalgia care, while noting most included trials had unclear risk of bias.

70/100
Evidence StrengthModerate
Study Quality
Sample Size
Replication

Key Findings

CBT and ACT modestly reduced depression in fibromyalgiaHigh

The pooled effect of CBT/ACT interventions on depressive symptoms at post-test was a standardized mean difference of −0.31 (95% CI −0.47 to −0.15; Z = 3.72, p = 0.0002), a statistically significant but modest-to-moderate effect. Individual effect sizes were significant in 3 studies that used a passive (waitlist/no-treatment) control.

Effects on anxiety were significant but weakerMedium

The pooled effect on anxiety severity was a standardized mean difference of −0.15 (95% CI −0.29 to −0.02; Z = 2.18, p = 0.03), described by the authors as statistically significant but weaker than the depression effect. Substantial individual improvement was seen in one study comparing CBT with an educational program.

CBT trials greatly outnumbered ACT trialsMedium

Of the 17 included studies, 13 applied CBT protocols and only 4 applied ACT. The authors attribute this imbalance to CBT's longer tradition and note that ACT requires further exploration in fibromyalgia patients with comorbid emotional disorders.

Most evidence came from trials with unclear risk of biasMedium

The majority of included studies had an unclear overall risk of bias. 'Selective reporting' had the lowest risk of bias, while 'incomplete outcome data' had the highest, reflecting increased attrition in psychological-intervention trials. Funnel plot inspection of depression scores suggested a reduced likelihood of publication bias.

Narrowly focused interventions (e.g., sleep) helped anxietyLow

The authors observed that interventions with a narrower focus, such as reducing sleep problems, appeared particularly useful for treating anxiety symptoms, consistent with prior evidence that CBT for insomnia may improve general wellbeing and mental health in fibromyalgia.

Study Methodology
Study Design
Systematic review and random-effects meta-analysis of randomized clinical trials, conducted per PRISMA 2009 and Cochrane Collaboration guidelines; protocol registered on PROSPERO (CRD42022354119). Standardized mean differences pooled in RevMan 5.4; heterogeneity via Chi2 and I2; publication bias via funnel plot.
Sample Size
17 randomized clinical trials comprising 1,499 fibromyalgia patients (individual study sample sizes ranged from 31 to 230)
Duration
Interventions averaged 10 sessions/modules of about 95 minutes each; literature search covered articles published January 2020 to March 2023 (last search March 2023)
Population
Adults with fibromyalgia diagnosed by a rheumatologist per American College of Rheumatology criteria; samples were demographically homogenous (predominantly women) with similar age, gender, occupational, and marital status across studies
Outcome Measures
Depression symptom severity at post-test · Anxiety symptom severity at post-test · Standardized mean difference (SMD) · Heterogeneity (Chi2, I2) · Risk of bias (Cochrane Collaboration tool)

Strengths

  • Followed PRISMA 2009 and Cochrane methodology with a pre-registered PROSPERO protocol (CRD42022354119)
  • Included only randomized clinical trials with control groups and rheumatologist-confirmed fibromyalgia diagnoses
  • Substantial pooled sample of 1,499 participants across 17 trials
  • Independent dual screening and risk-of-bias assessment with third-reviewer arbitration
  • Funnel plot inspection suggested low likelihood of publication bias for the depression outcome
  • Low heterogeneity for the anxiety analysis (I2 = 11%)

Limitations

  • Most included studies had an unclear overall risk of bias, and 'incomplete outcome data' (attrition) was a notable weakness
  • Homogenous sample characteristics limit generalizability to the broader fibromyalgia population
  • Change processes such as reduction in pain catastrophizing (CBT) or increased pain acceptance (ACT) were not analyzed, as few studies reported them
  • Multimodal/complex interventions combining psychotherapy with medication and physical therapy were excluded
  • Far fewer ACT trials (4) than CBT trials (13), limiting conclusions about ACT specifically
  • Considerable variability among depression outcome reports (I2 = 42%)

Key Takeaways for Patients

What This Means for You

  1. 01Talking therapies such as cognitive-behavioral therapy (CBT) and acceptance and commitment therapy (ACT) may modestly ease the depression and anxiety that often come with fibromyalgia.
  2. 02These therapies are meant to work alongside (not replace) standard medical treatment as part of a combined care plan.
  3. 03The benefit for depression was larger and more consistent than the benefit for anxiety, which was smaller though still measurable.
  4. 04Most studies used about 10 sessions averaging roughly an hour and a half, delivered individually or in groups and sometimes by phone or online.
  5. 05Because many of the underlying studies had uncertain quality, these findings are encouraging rather than definitive.

Read the Full Paper

Access the complete peer-reviewed study from Medicine and Pharmacy Reports (Med Pharm Rep)

View Full Study

Related Research

●●●●● LandmarkSystematic Review

Effectiveness of Percutaneous Needle Electrolysis (PNE) and Intramuscular Electrical Stimulation (IMES) in the Management of Myofascial Pain Syndrome and Tendinopathies: A Systematic Review

Trybulski et al.·Journal of Clinical Medicine·2026

This systematic review found that PNE and IMES may improve pain and function in myofascial pain syndrome and tendinopathies, but evidence quality was limited by high risk of bias. Both techniques appear safe with only minor, self-limiting adverse events.

Systematic Reviews & Meta-analysesRead →
●●●●● LandmarkMeta-analysis

Efficacy of cognitive behavioral therapy for musculoskeletal pain: a systematic review and meta-analysis

Xianjun Liu et al.·Frontiers in Psychology·2026

A meta-analysis of 14 RCTs found that CBT-based interventions produce small-to-moderate reductions in pain intensity and the largest, most consistent reductions in pain catastrophizing for chronic musculoskeletal pain.

Central SensitizationRead →
●●●●● LandmarkSystematic Review

Dry Needling in Sports and Sport Recovery: A Systematic Review with an Evidence Gap Map

Kużdżał et al.·Sports Medicine·2025

This systematic review of 24 studies found dry needling effectively reduces pain in injured athletes but shows mixed results for performance enhancement in healthy athletes. Significant research gaps exist for elite athletes and long-term effects.

Systematic Reviews & Meta-analysesRead →
●●●●● LandmarkMeta-analysis

Effectiveness of Pain Neuroscience Education in Reducing Pain, Disability, Kinesiophobia, and Catastrophizing in Patients with Chronic Low Back Pain: A Systematic Review and Meta-Analysis

Luisa Medina-Viedma et al.·Medical Sciences (Basel)·2025

A meta-analysis of 15 RCTs (810 patients) found that pain neuroscience education, usually added to exercise or physiotherapy, may reduce pain, disability, kinesiophobia, and catastrophizing in chronic low back pain, though the authors urge caution given small trials and heterogeneity.

Central SensitizationRead →